Filing summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) filed this Form 8-K under Item 5.02 to report executive compensation arrangements and the formation of a subsidiary. The reported events were effective September 24, 2026; the filing was signed September 30, 2026.
Financial and operating information
This filing does not report quarterly or annual financial results, cash flow, margins, debt, or liquidity. It describes performance targets for future executive awards, not reported company results. It cites approximately $30 billion as the new-product annual revenue level associated with maximum PSU earnout, approximately double Regeneron’s total 2025 revenue.
Executive awards and material changes
- The independent, non-employee Board members approved one-time performance share unit awards for CEO Leonard S. Schleifer and CSO George D. Yancopoulos under the company’s 2014 Long-Term Incentive Plan.
- The awards replace annual long-term incentive equity awards for both executives until 2036. The 10-year performance period runs through December 31, 2035, and delivered shares generally cannot be sold until February 2036, subject to limited exceptions.
- Maximum awards are capped at 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. The filing does not state the number of PSUs initially granted to each executive.
- Earnout is tied to new-product filings and approvals and, more substantially, revenue from qualifying new products. Below $10 billion in new-product annual revenue, no revenue-based PSUs are earned; activity-based earnout is capped at 100,000 PSUs for the CEO and 300,000 for the CSO. Between $10 billion and $30 billion, activity-based PSUs may not exceed 30% of the aggregate eligible award.
- A relative total shareholder return modifier can adjust earned PSUs by up to 20% in either direction versus the NASDAQ Biotechnology Total Return Index over the performance period. Earlier deliveries are subject to a 20% holdback pending the final adjustment.
Outlook, conditions, and risks
- Maximum earnout requires nearly $30 billion in qualifying new-product annual revenue, substantial pipeline advancement, positive absolute TSR, and outperformance against the benchmark. The filing notes execution challenges, including increasing biosimilar and branded competition to existing products.
- Earnout and delivery are deliberately limited in earlier years: no revenue-based PSUs may be earned before certification of 2032 revenue, activity-based earnout is capped through 2031, aggregate earnout is capped through 2033, and further delivery limits apply before 2035.
- Only sales from products receiving FDA approval during the performance period generally count. Lynozyfic and Otarmeni count only if they receive significant label expansions; acquired-product revenue counts only above the pre-acquisition baseline.
- Continued service is generally required through applicable measurement dates. Voluntary departure or retirement before those dates results in forfeiture of unvested PSUs; qualifying termination protections apply. The awards also require good-faith participation in succession planning, with formal plans due by the fifth grant anniversary.
- Regeneron formed a majority-owned and controlled subsidiary to explore a potential non-core opportunity. The subsidiary has nominal value, no significant assets, and has not commenced operations; it may not pursue the opportunity. Each executive received an equity stake, part of which is subject to vesting.
Important facts for investors to verify
- Review Exhibits 10.1, 10.2, and 99.1 for full award terms, payout schedules, termination provisions, and the precise performance-goal mechanics.
- Verify the initial PSU award amounts and the treatment of any early delivery against the award agreements.
- Monitor the subsidiary’s subsequent development, capitalization, operations, and the terms of the executives’ equity stakes when disclosed in the referenced Form 10-Q.
- Assess the long-term revenue and pipeline targets alongside competitive pressures and the substantial service and holding-period requirements.